Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
COCH 
Envoy Medical Inc. (COCH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: COCH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.88
1 Year Target Price $6.88
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.17% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 26.04M USD | Price to earnings Ratio - | 1Y Target Price 6.88 |
Price to earnings Ratio - | 1Y Target Price 6.88 | ||
Volume (30-day avg) 4 | Beta 2.2 | 52 Weeks Range 1.06 - 3.99 | Updated Date 08/29/2025 |
52 Weeks Range 1.06 - 3.99 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.41 |
Earnings Date
Report Date 2025-07-31 | When - | Estimate -0.2 | Actual -0.32 |
Profitability
Profit Margin - | Operating Margin (TTM) -6500% |
Management Effectiveness
Return on Assets (TTM) -148% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 49586327 | Price to Sales(TTM) 117.3 |
Enterprise Value 49586327 | Price to Sales(TTM) 117.3 | ||
Enterprise Value to Revenue 223.36 | Enterprise Value to EBITDA -1.35 | Shares Outstanding 21520900 | Shares Floating 10852576 |
Shares Outstanding 21520900 | Shares Floating 10852576 | ||
Percent Insiders 49.46 | Percent Institutions 59.25 |
Upturn AI SWOT
Envoy Medical Inc.
Company Overview
History and Background
Envoy Medical, formerly known as Sound ID, was founded to develop implantable medical devices for hearing loss. Their flagship product is the Esteem fully implantable hearing aid.
Core Business Areas
- Hearing Restoration: Focuses on the development, manufacturing, and commercialization of fully implanted hearing devices designed to restore natural hearing.
Leadership and Structure
Details regarding the specific leadership team and organizational structure are not readily available in public sources. Publicly traded under ticker symbol (NVY)
Top Products and Market Share
Key Offerings
- Esteem: The Esteem is a fully implanted hearing aid. It uses the natural mechanics of the ear to provide hearing amplification. Market share data is difficult to determine due to the niche market, high cost and low-volume manufacturing. Competitors include Cochlear Limited (cochlear implants) and conventional hearing aid manufacturers such as Sonova (phonak), Demant (oticon), and WS Audiology (widex).
Market Dynamics
Industry Overview
The hearing aid market is characterized by an aging population and increasing awareness of hearing loss. Technological advancements, such as miniaturization and improved signal processing, are driving growth. Cochlear implants and bone-anchored hearing aids represent significant segments, in addition to traditional hearing aids.
Positioning
Envoy Medical occupies a niche position with its fully implanted Esteem device, targeting patients seeking a discreet and natural hearing solution. Their competitive advantage lies in the absence of external components.
Total Addressable Market (TAM)
The global hearing aids market is projected to reach $13.7 billion by 2028. Envoy Medical's position depends on the adoption of their fully implanted technology and their ability to capture a segment of the premium hearing solutions market.
Upturn SWOT Analysis
Strengths
- Fully implanted technology
- Discreet design
- Natural sound quality
Weaknesses
- High cost
- Limited availability
- Surgical procedure required
- Small market penetration
Opportunities
- Expanding global reach
- Developing new applications
- Partnering with ENT specialists
- Technological advancements
Threats
- Competition from established hearing aid manufacturers
- Technological advancements in hearing aid technology
- Reimbursement challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- Cochlear Ltd. (COCH.AX)
- Sonova Holding AG (SONVX.SW)
- Demant A/S (DEMANT.CO)
Competitive Landscape
Envoy Medical's competitive advantage is its fully implanted design. However, it faces challenges due to its high cost, limited availability, and the need for surgical implantation, competing against larger, more established players with wider product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's stage of development and recent IPO.
Future Projections: Future projections depend on successful commercialization of the Esteem device and gaining market share. Analyst estimates may become available as the company establishes a trading history.
Recent Initiatives: Recent initiatives include commercialization efforts for the Esteem and securing regulatory approvals.
Summary
Envoy Medical is a company pioneering fully implanted hearing solutions. It has the potential for significant growth. However, the high cost and the nature of the medical device market presents significant challenges. It will have to address the market for conventional hearing aids which is the most significant barrier.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Market Research Reports
- Public Filings
Disclaimers:
The information provided is for general informational purposes only and should not be construed as investment advice. Market share data is approximate and based on available information. Financial data is limited due to the company's early stage.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Envoy Medical Inc.
Exchange NASDAQ | Headquaters White Bear Lake, MN, United States | ||
IPO Launch date 2021-04-29 | CEO & Director Mr. Brent T. Lucas Esq. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 42 | Website https://www.envoymedical.com |
Full time employees 42 | Website https://www.envoymedical.com | ||
Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.